Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Byvasda (bevacizumab biosimilar)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Etana, Innovent Biologics

Drug class:

VEGF-A inhibitor

Related drugs:

‹

Equidacent (bevacizumab biosimilar) (0)

GB222 (bevacizumab biosimilar) (0)

HLX-04 (bevacizumab biosimilar) (0)

ranibizumab (0)

Pusintin (bevacizumab biosimilar) (0)

TRS003 (bevacizumab biosimilar) (0)

HD204 (bevacizumab biosimilar) (0)

bevacizumab biosimilar (0)

hVEGF26–104/RFASE (0)

bevacizumab (416)

Aybintio (bevacizumab biosimilar) (14)

bevacizumab-maly (12)

bevacizumab-awwb (11)

bevacizumab-adcd (11)

bevacizumab-tnjn (8)

bevacizumab-bvzr (8)

Krabeva (bevacizumab biosimilar) (7)

ziv-aflibercept IV (4)

SIBP-04 (bevacizumab biosimilar) (1)

BP102 (bevacizumab biosimilar) (0)

SCT510 (bevacizumab biosimilar) (0)

Ankada (bevacizumab biosimilar) (0)

BI 695502 (bevacizumab biosimilar) (0)

MIL 60 (bevacizumab biosimilar) (0)

LY01008 (bevacizumab biosimilar) (0)

CBT124 (bevacizumab biosimilar) (0)

Cizumab (bevacizumab biosimilar) (0)

Equidacent (bevacizumab biosimilar) (0)

GB222 (bevacizumab biosimilar) (0)

HLX-04 (bevacizumab biosimilar) (0)

ranibizumab (0)

Pusintin (bevacizumab biosimilar) (0)

TRS003 (bevacizumab biosimilar) (0)

HD204 (bevacizumab biosimilar) (0)

bevacizumab biosimilar (0)

hVEGF26–104/RFASE (0)

›

No biomarker	Glioblastoma	No biomarker	Glioblastoma	Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval Byvasda (bevacizumab biosimilar) Sensitive : A1	Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval Byvasda (bevacizumab biosimilar) Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval sintilimab + Byvasda (bevacizumab biosimilar) Sensitive : A1	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval sintilimab + Byvasda (bevacizumab biosimilar) Sensitive : A1
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval sintilimab + Byvasda (bevacizumab biosimilar) Sensitive : A1	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval sintilimab + Byvasda (bevacizumab biosimilar) Sensitive : A1
TNFRSF9 elevation	Hepatocellular Cancer	TNFRSF9 elevation	Hepatocellular Cancer	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: C3 – Early Trials sintilimab + Byvasda (bevacizumab biosimilar) Sensitive : C3	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: C3 – Early Trials sintilimab + Byvasda (bevacizumab biosimilar) Sensitive : C3